Work

Epoxygenase Pathways of Arachidonic Acid Metabolism

Year: 2001
Type: review
Abstract: arachidonic acid cis-epoxyeicosatrienoic acid dihydroxyeicosatrienoic acid hydroxyeicosatetraenoic acid soluble epoxide hydrolase prostaglandin H synthase lipoxygenase tetrahydrofuran phospholipid fatty acid-binding protein endothelial derived hyperpolarizing factor tissue plasminogen activator Arachidonic acid (AA)1 is present in vivo esterified to cell membrane glycerophospholipids. Activation of phospholipases (e.g. cytosolic phospholipase A2) releases free AA from the phospholipid (PL) pools and makes it available for oxidative metabolism by several enzyme systems (Fig. 1). The prostaglandin endoperoxide H synthases (PGHSs) metabolize AA to PGH2, which serves as the precursor of the prostaglandins, thromboxane and prostacyclin (1Smith W.L. Garavito R.M. DeWitt D.L. J. Biol. Chem. 1996; 271: 33157-33160Abstract Full Text Full Text PDF PubMed Scopus (1860) Google Scholar). The lipoxygenases (LOXs) convert AA to labile hydroperoxy intermediates that go on to form the leukotrienes, hydroxyeicosatetraenoic acids (HETEs) and lipoxins (2Brash A.R. J. Biol. Chem. 1999; 274: 23679-23682Abstract Full Text Full Text PDF PubMed Scopus (1155) Google Scholar). The PGHSs and LOXs have been extensively studied, and their eicosanoid products have been shown to play important functional roles in a variety of fundamental biological processes such as inflammation, cellular proliferation, and intracellular signaling (1Smith W.L. Garavito R.M. DeWitt D.L. J. Biol. Chem. 1996; 271: 33157-33160Abstract Full Text Full Text PDF PubMed Scopus (1860) Google Scholar, 2Brash A.R. J. Biol. Chem. 1999; 274: 23679-23682Abstract Full Text Full Text PDF PubMed Scopus (1155) Google Scholar). In contrast, less is known about the “third pathway” of AA metabolism wherein multiple cytochromes P450 metabolize AA to three types of eicosanoid products (3Capdevila J.H. Falck J.R. Harris R.C. J. Lipid Res. 2000; 41: 163-181Abstract Full Text Full Text PDF PubMed Google Scholar, 4Oliw E.H. Prog. Lipid Res. 1994; 33: 329-354Crossref PubMed Scopus (139) Google Scholar, 5Makita K. Falck J.R. Capdevila J.H. FASEB J. 1996; 10: 1456-1463Crossref PubMed Scopus (120) Google Scholar, 6McGiff J.C. Quilley J. Curr. Opin. Nephrol. Hypertens. 2001; 10: 231-237Crossref PubMed Scopus (86) Google Scholar). Allylic oxidation forms several midchain conjugated dienols (5-, 8-, 9-, 11-, 12-, and 15-HETEs). ω-terminal hydroxylation forms C16–C20 alcohols of AA (16-, 17-, 18-, 19-, and 20-HETEs). Olefin epoxidation (also called the epoxygenase reaction) results in the production of fourcis-epoxyeicosatrienoic acids (14,15-, 11,12-, 8,9-, and 5,6-EETs), each of which can be formed as either the R,S or the S,R enantiomer (Fig. 2). Studies have demonstrated that P450 epoxygenase-derived eicosanoids have a multitude of potent biological activities. For example, EETs have been shown to have potent effects on peptide hormone secretion (7Cashman J.R. Hanks D. Weiner R.I. Neuroendocrinology. 1987; 46: 246-251Crossref PubMed Scopus (48) Google Scholar, 8Falck J.R. Manna S. Moltz J. Chacos N. Capdevila J. Biochem. Biophys. Res. Commun. 1983; 114: 743-749Crossref PubMed Scopus (147) Google Scholar, 9Snyder G.D. Yadagiri P. Falck J.R. Am. J. Physiol. 1989; 256: E221-E226PubMed Google Scholar), vascular and bronchial smooth muscle tone (10Campbell W.B. Gebremedhin D. Pratt P.F. Harder D.R. Circ. Res. 1996; 78: 415-423Crossref PubMed Scopus (1115) Google Scholar, 11Proctor K.G. Falck J.R. Capdevila J. Circ. Res. 1987; 60: 50-59Crossref PubMed Scopus (153) Google Scholar, 12Zou A.P. Fleming J.T. Falck J.R. Jacobs E.R. Gebremedhin D. Harder D.R. Roman R.J. Am. J. Physiol. 1996; 270: F822-F832PubMed Google Scholar, 13Zhu D. Bousamra M. Zeldin D.C. Falck J.R. Townsley M. Harder D.R. Roman R.J. Jacobs E.R. Am. J. Physiol. 2000; 278: L335-L343PubMed Google Scholar, 14Harder D.R. Campbell W.B. Roman R.J. J. Vasc. Res. 1995; 32: 79-92Crossref PubMed Scopus (279) Google Scholar, 15Zeldin D.C. Plitman J.D. Kobayashi J. Miller R.F. Snapper J.R. Falck J.R. Szarek J.L. Philpot R.M. Capdevila J.H. J. Clin. Invest. 1995; 95: 2150-2160Crossref PubMed Scopus (105) Google Scholar), and ionic transport (16Harris R.C. Homma T. Jacobson H.R. Capdevila J. J. Cell. Physiol. 1990; 144: 429-437Crossref PubMed Scopus (92) Google Scholar, 17Romero M.F. Madhun Z.T. Hopfer U. Douglas J.G. Adv. Prostaglandin Thromboxane Leukotriene Res. 1991; 21A: 205-208PubMed Google Scholar, 18Pascual J.M. McKenzie A. Yankaskas J.R. Falck J.R. Zeldin D.C. J. Pharmacol. Exp. Ther. 1998; 286: 772-779PubMed Google Scholar). The EETs have also been shown to play critical roles in regulating cellular proliferation (16Harris R.C. Homma T. Jacobson H.R. Capdevila J. J. Cell. Physiol. 1990; 144: 429-437Crossref PubMed Scopus (92) Google Scholar, 19Chen J.K. Falck J.R. Reddy K.M. Capdevila J. Harris R.C. J. Biol. Chem. 1998; 273: 29254-29261Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar, 20Sheu H.L. Omata K. Utsumi Y. Tsutsumi E. Sato T. Shimizu T. Abe K. Adv. Prostaglandin Thromboxane Leukotriene Res. 1995; 23: 211-213PubMed Google Scholar), inflammation (21Node K. Huo Y. Ruan X. Yang B. Spiecker M. Ley K. Zeldin D.C. Liao J.K. Science. 1999; 285: 1276-1279Crossref PubMed Scopus (1024) Google Scholar), hemostasis (22Node K. Ruan X.L. Dai J. Yang S.X. Graham L. Zeldin D.C. Liao J.K. J. Biol. Chem. 2001; 276: 15983-15989Abstract Full Text Full Text PDF PubMed Scopus (212) Google Scholar), and a variety of intracellular signaling pathways (19Chen J.K. Falck J.R. Reddy K.M. Capdevila J. Harris R.C. J. Biol. Chem. 1998; 273: 29254-29261Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar, 23Burns K.D. Capdevila J. Wei S. Breyer M.D. Homma T. Harris R.C. Am. J. Physiol. 1995; 269: C831-C840Crossref PubMed Google Scholar, 24Chen J.K. Capdevila J. Harris R.C. J. Biol. Chem. 2000; 275: 13789-13792Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar, 25Dulin N.O. Alexander L.D. Harwalkar S. Falck J.R. Douglas J.G. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8098-8102Crossref PubMed Scopus (77) Google Scholar, 26Hoebel B.G. Graier W.F. Eur. J. Pharmacol. 1998; 346: 115-117Crossref PubMed Scopus (45) Google Scholar, 27Rzigalinski B.A. Willoughby K.A. Hoffman S.W. Falck J.R. Ellis E.F. J. Biol. Chem. 1999; 274: 175-182Abstract Full Text Full Text PDF PubMed Scopus (121) Google Scholar). This minireview will provide a general overview of the AA epoxygenase pathway with emphasis on the P450 enzymes involved in EET biosynthesis, the metabolic fate of the EETs once they are formed, and the biological relevance of the EETs in the kidney and cardiovascular system.Figure 2EET stereoisomers. Each of the four EET regioisomers can be biosynthesized as either the R,S or theS,R enantiomer.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Studies using purified and/or recombinant P450 enzymes have demonstrated that multiple P450s can metabolize AA to EETs, albeit with different catalytic efficiencies. Thus, members of the mammalian CYP1A, CYP2B, CYP2C, CYP2D, CYP2G, CYP2J, CYP2N, and CYP4A subfamilies have been shown to be capable of EET biosynthesis in vitro(28Rifkind A.B. Lee C. Chang T.K. Waxman D.J. Arch. Biochem. Biophys. 1995; 320: 380-389Crossref PubMed Scopus (219) Google Scholar, 29Keeney D.S. Skinner C. Wei S. Friedberg T. Waterman M.R. J. Biol. Chem. 1998; 273: 9279-9284Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar, 30Zeldin D.C. DuBois R.N. Falck J.R. Capdevila J.H. Arch. Biochem. Biophys. 1995; 322: 76-86Crossref PubMed Scopus (156) Google Scholar, 31Thompson C.M. Capdevila J.H. Strobel H.W. J. Pharmacol. Exp. Ther. 2000; 294: 1120-1130PubMed Google Scholar, 32Oleksiak M.F. Wu S. Parker C. Karchner S.I. Stegeman J.J. Zeldin D.C. J. Biol. Chem. 2000; 275: 2312-2321Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar, 33Nguyen X. Wang M.H. Reddy K.M. Falck J.R. Schwartzman M.L. Am. J. Physiol. 1999; 276: R1691-R1700PubMed Google Scholar, 34Wu S. Moomaw C.R. Tomer K.B. Falck J.R. Zeldin D.C. J. Biol. Chem. 1996; 271: 3460-3468Abstract Full Text Full Text PDF PubMed Scopus (426) Google Scholar, 35Capdevila J.H. Karara A. Waxman D.J. Martin M.V. Falck J.R. Guengerich F.P. J. Biol. Chem. 1990; 265: 10865-10871Abstract Full Text PDF PubMed Google Scholar, 36Laethem R.M. Laethem C.L. Ding X. Koop D.R. J. Pharmacol. Exp. Ther. 1992; 262: 433-438PubMed Google Scholar). In general, the regioselectivity of EET formation is P450 isoform-specific. For example, CYP2C8 forms 14,15-EET and 11,12-EET in a ratio of 1.3:1.0 but does not produce significant amounts of 8,9-EET. In contrast, CYP2C9, which is >80% identical to CYP2C8, produces 14,15-EET, 11,12-EET, and 8,9-EET in a ratio of 2.3:1.0:0.5 (30Zeldin D.C. DuBois R.N. Falck J.R. Capdevila J.H. Arch. Biochem. Biophys. 1995; 322: 76-86Crossref PubMed Scopus (156) Google Scholar, 37Daikh B.E. Lasker J.M. Raucy J.L. Koop D.R. J. Pharmacol. Exp. Ther. 1994; 271: 1427-1433PubMed Google Scholar). The stereoselectivity of EET biosynthesis also depends on the P450 isoform involved in catalysis. Thus, CYP2C8 produces (14R,15S)-EET and (11R,12S)-EET with optical purities of 86 and 81%, respectively. In contrast, CYP2C9 produces (14R,15S)-EET and (11S,12R)-EETs with significantly lower optical purities (63 and 69%, respectively) (30Zeldin D.C. DuBois R.N. Falck J.R. Capdevila J.H. Arch. Biochem. Biophys. 1995; 322: 76-86Crossref PubMed Scopus (156) Google Scholar, 37Daikh B.E. Lasker J.M. Raucy J.L. Koop D.R. J. Pharmacol. Exp. Ther. 1994; 271: 1427-1433PubMed Google Scholar). Multiple P450s may contribute to EET biosynthesis in a given tissue or cell type. Moreover, the contribution of an individual P450 isoform will depend on both its organ/cellular abundance and its catalytic efficiency. For example, in human and rat liver, CYP2C isoforms are highly expressed and likely contribute significantly to EET biosynthesis. Indeed, polyclonal antibodies to CYP2C isoforms inhibit >70% of hepatic microsomal AA epoxygenase activity (37Daikh B.E. Lasker J.M. Raucy J.L. Koop D.R. J. Pharmacol. Exp. Ther. 1994; 271: 1427-1433PubMed Google Scholar, 38Zeldin D.C. Moomaw C.R. Jesse N. Tomer K.B. Beetham J. Hammock B.D. Wu S. Arch. Biochem. Biophys. 1996; 330: 87-96Crossref PubMed Scopus (129) Google Scholar, 39Capdevila J. Zeldin D.C. Karara A. Falck J.F. Adv. Mol. Cell Biol. 1996; 14: 317-339Crossref Scopus (9) Google Scholar). Similarly, in human and rat kidney, CYP2C isoforms are responsible for the majority of EET biosynthesis (30Zeldin D.C. DuBois R.N. Falck J.R. Capdevila J.H. Arch. Biochem. Biophys. 1995; 322: 76-86Crossref PubMed Scopus (156) Google Scholar, 40Holla V.R. Makita K. Zaphiropoulos P.G. Capdevila J.H. J. Clin. Invest. 1999; 104: 751-760Crossref PubMed Scopus (110) Google Scholar). In contrast, in human and rat heart, CYP2J isoforms are particularly abundant and have been proposed to be the predominant enzymes responsible for epoxidation of endogenous AA pools (34Wu S. Moomaw C.R. Tomer K.B. Falck J.R. Zeldin D.C. J. Biol. Chem. 1996; 271: 3460-3468Abstract Full Text Full Text PDF PubMed Scopus (426) Google Scholar, 41Wu S. Chen W. Murphy E. Gabel S. Tomer K.B. Foley J. Steenbergen C. Falck J.R. Moomaw C.R. Zeldin D.C. J. Biol. Chem. 1997; 272: 12551-12559Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar). Both CYP2J and CYP2C isoforms appear to contribute to EET biosynthesis in vascular endothelial cells, although their relative contribution remains unknown (21Node K. Huo Y. Ruan X. Yang B. Spiecker M. Ley K. Zeldin D.C. Liao J.K. Science. 1999; 285: 1276-1279Crossref PubMed Scopus (1024) Google Scholar, 42Fisslthaler B. Popp R. Kiss L. Potente M. Harder D.R. Fleming I. Busse R. Nature. 1999; 401: 493-497Crossref PubMed Scopus (809) Google Scholar, 43Campbell W.B. Trends Pharmacol. Sci. 2000; 21: 125-127Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar, 44Zeldin D.C. Liao J.K. Trends Pharmacol. Sci. 2000; 21: 127-128Abstract Full Text Full Text PDF PubMed Google Scholar). In most tissues, however, the relative contribution of different P450s to EET biosynthesis remains unknown due to the absence of P450 isoform-specific chemical inhibitors and inhibitory antibodies. EET biosynthesis can be altered by factors that affect P450 expression and/or activity. Treatment of rats with phenobarbital induces CYP2B subfamily P450s leading to increased hepatic AA epoxygenase activity and altered regio- and stereochemical selectivity of rat liver EETs (35Capdevila J.H. Karara A. Waxman D.J. Martin M.V. Falck J.R. Guengerich F.P. J. Biol. Chem. 1990; 265: 10865-10871Abstract Full Text PDF PubMed Google Scholar, 45Karara A. Dishman E. Blair I. Falck J.R. Capdevila J.H. J. Biol. Chem. 1989; 264: 19822-19827Abstract Full Text PDF PubMed Google Scholar). In contrast, treatment of rats with the aromatic hydrocarbon β-naphthoflavone results in reduced hepatic AA epoxygenase activity and a concomitant increase in the formation of ω-terminal HETEs (35Capdevila J.H. Karara A. Waxman D.J. Martin M.V. Falck J.R. Guengerich F.P. J. Biol. Chem. 1990; 265: 10865-10871Abstract Full Text PDF PubMed Google Scholar). The effects of aromatic hydrocarbons on P450 epoxygenase activity are species-dependent. Treatment of fish and avian species with benzo(a)pyrene or 2,3,7,8-tetrachlorodibenzo-p-dioxin increases hepatic EET biosynthesis, likely by inducing CYP1A subfamily P450s (46Schlezinger J.J. Parker C. Zeldin D.C. Stegeman J.J. Arch. Biochem. Biophys. 1998; 353: 265-275Crossref PubMed Scopus (34) Google Scholar, 47Gilday D. Bellward G.D. Sanderson J.T. Janz D.M. Rifkind A.B. Toxicol. Appl. Pharmacol. 1998; 150: 106-116Crossref PubMed Scopus (31) Google Scholar). Nutritional factors can AA to reduced hepatic expression and epoxygenase activity in rats W. J. P. C. Parker C. Zeldin D.C. Mol. Pharmacol. 1998; PubMed Scopus Google Scholar). EET biosynthesis is increased in vascular tissue from a with that P450 AA metabolism Falck J.R. Campbell W.B. Am. J. Physiol. 1991; Google Scholar). been shown to rat kidney in increased EET biosynthesis and secretion of epoxygenase V.R. Makita K. Zaphiropoulos P.G. Capdevila J.H. J. Clin. Invest. 1999; 104: 751-760Crossref PubMed Scopus (110) Google Scholar, J.H. Wei S. J. Karara A. Jacobson H.R. Falck J.R. Guengerich F.P. DuBois R.N. J. Biol. Chem. 1992; Full Text PDF PubMed Google Scholar, T. D. Quilley J. J.C. J. Clin. Invest. 1999; 104: PubMed Scopus Google Scholar). in human P450 is however, is known about the of P450 on AA metabolic in the which both and acid been shown to in significantly reduced AA epoxygenase activity D. Zeldin D.C. B. 2001; PubMed Scopus Google Scholar). have several the that in acid that affect P450 enzyme and D. C. is not known the of is altered in formed, the EETs can be a of pathways as in Capdevila and J.H. Dishman E. Blair Falck J.R. Biochem. Biophys. Res. Commun. 1987; PubMed Scopus Google Scholar, A. Dishman E. Falck J.R. Capdevila J.H. J. Biol. Chem. 1991; Full Text PDF PubMed Google have the of that an esterified to the are formed in vivo by a by P450 epoxidation of AA by to and regio- and A. Dishman E. Falck J.R. Capdevila J.H. J. Biol. Chem. 1991; Full Text PDF PubMed Google Scholar). In the majority of endogenous EETs present in mammalian are esterified to cellular glycerophospholipids. it been shown that significantly the activity of that may be involved in the of membrane J. Capdevila J.H. Zeldin D.C. Mol. Pharmacol. 1999; PubMed Scopus Google Scholar). EETs can be to their acids by soluble epoxide hydrolase N. Capdevila J. Falck J.R. Manna S. C. Hammock B.D. Arch. Biochem. Biophys. 1983; PubMed Scopus Google Scholar, D.C. Kobayashi J. Falck J.R. Hammock B.D. Snapper J.R. Capdevila J.H. J. Biol. Chem. Full Text PDF PubMed Google Scholar, D.C. Wei S. Falck J.R. Hammock B.D. Snapper J.R. Capdevila J.H. Arch. Biochem. Biophys. 1995; PubMed Scopus Google Scholar, M. K. B. Hammock B.D. Biophys. 1996; PubMed Scopus Google Scholar). The microsomal epoxide hydrolase can also metabolize EETs, albeit significantly lower The of as endogenous of liver, and that EET in vivo D.C. Plitman J.D. Kobayashi J. Miller R.F. Snapper J.R. Falck J.R. Szarek J.L. Philpot R.M. Capdevila J.H. J. Clin. Invest. 1995; 95: 2150-2160Crossref PubMed Scopus (105) Google Scholar, 38Zeldin D.C. Moomaw C.R. Jesse N. Tomer K.B. Beetham J. Hammock B.D. Wu S. Arch. Biochem. Biophys. 1996; 330: 87-96Crossref PubMed Scopus (129) Google Scholar, J. D.J. E. Adv. Prostaglandin Thromboxane Leukotriene Res. 1991; 21A: Google Scholar). The metabolism of EETs by is highly with 14,15-EET the The of 11,12-EET and 8,9-EET by significantly lower and is a for enzyme D.C. Kobayashi J. Falck J.R. Hammock B.D. Snapper J.R. Capdevila J.H. J. Biol. Chem. Full Text PDF PubMed Google Scholar). The metabolism of EETs by is also highly for the and D.C. Kobayashi J. Falck J.R. Hammock B.D. Snapper J.R. Capdevila J.H. J. Biol. Chem. Full Text PDF PubMed Google Scholar). are to a EETs, X. M. P. Am. J. Physiol. 1999; Google have that the of EETs to their been as a EETs are have been shown to be in the and are inhibitors of the of in the kidney X. M. Circ. Res. 1996; PubMed Scopus Google Scholar, D.L. Capdevila J. Falck J.R. Breyer M.D. Jacobson H.R. J. Clin. Invest. 1989; PubMed Scopus Google Scholar, C.L. M. Circ. Res. 1998; PubMed Scopus Google Scholar). of EETs with rat or liver microsomal P450 results in the production of a of acids and acids M. K. B. Hammock B.D. Biophys. 1996; PubMed Scopus Google Scholar, J.H. P. Yadagiri P. S. Falck J.R. Arch. Biochem. Biophys. PubMed Scopus Google Scholar). The can be by to which to the M. K. B. Hammock B.D. Biophys. 1996; PubMed Scopus Google Scholar). is known the biological relevance of the and Both 8,9-EET and are for C. K. Blair Biochem. Biophys. Res. Commun. 1992; PubMed Scopus Google Scholar, M. P. Falck J.R. J.C. J. Biol. Chem. Full Text PDF PubMed Google Scholar, T. Shimizu T. C. Blair Harris R.C. Biochem. Biophys. Res. Commun. PubMed Scopus Google Scholar). is to both and in the is to as a is activity M. P. Falck J.R. J.C. J. Biol. Chem. Full Text PDF PubMed Google Scholar). 8,9-EET is to acid and acid by the acid been shown to be a potent for rat T. Shimizu T. C. Blair Harris R.C. Biochem. Biophys. Res. Commun. PubMed Scopus Google Scholar). four EETs can also as for cytosolic to form a of the biological relevance of which is unknown Falck J.R. Manna S. Murphy R.C. Capdevila J. Arch. Biochem. Biophys. PubMed Scopus Google Scholar). X. M. Circ. Res. 1996; PubMed Scopus Google have several pathways of EET metabolism in endothelial 11,12-EET is to epoxide and This in the In the of epoxide hydrolase the biosynthesis of the several products and as as a X. S. C. Hammock B.D. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar). fatty acid-binding may EETs and their and/or 2001; PubMed Scopus Google have the relative of for several P450 epoxygenase-derived The of for and 11,12-EET for The liver and also for EETs that of EETs may their intracellular the of for may their from The biological relevance of EETs and/or in been the of a of (3Capdevila J.H. Falck J.R. Harris R.C. J. Lipid Res. 2000; 41: 163-181Abstract Full Text Full Text PDF PubMed Google Scholar, 4Oliw E.H. Prog. Lipid Res. 1994; 33: 329-354Crossref PubMed Scopus (139) Google Scholar, 5Makita K. Falck J.R. Capdevila J.H. FASEB J. 1996; 10: 1456-1463Crossref PubMed Scopus (120) Google Scholar, 6McGiff J.C. Quilley J. Curr. Opin. Nephrol. Hypertens. 2001; 10: 231-237Crossref PubMed Scopus (86) Google Scholar, 39Capdevila J. Zeldin D.C. Karara A. Falck J.F. Adv. Mol. Cell Biol. 1996; 14: 317-339Crossref Scopus (9) Google Scholar, E.R. Zeldin D.C. Am. J. Physiol. 2001; PubMed Google R.J. K.G. Harder D.R. M. Clin. Exp. Pharmacol. Physiol. 2000; PubMed Scopus Google Scholar). will on the of eicosanoids in kidney and cardiovascular in and cardiovascular effects of P450 epoxygenase on and R.C. Homma T. Jacobson H.R. Capdevila J. J. Cell. Physiol. 1990; 144: 429-437Crossref PubMed Scopus (92) Google Scholar, 17Romero M.F. Madhun Z.T. Hopfer U. Douglas J.G. Adv. Prostaglandin Thromboxane Leukotriene Res. 1991; 21A: 205-208PubMed Google Scholar, Z.T. D. Hopfer U. Douglas J.G. J. Clin. Invest. 1991; PubMed Scopus Google Scholar, T. J. Clin. Invest. PubMed Scopus Google in intracellular M.F. Madhun Z.T. Hopfer U. Douglas J.G. Adv. Prostaglandin Thromboxane Leukotriene Res. 1991; 21A: 205-208PubMed Google Scholar, 23Burns K.D. Capdevila J. Wei S. Breyer M.D. Homma T. Harris R.C. Am. J. Physiol. 1995; 269: C831-C840Crossref PubMed Google Scholar, Z.T. D. Hopfer U. Douglas J.G. J. Clin. Invest. 1991; PubMed Scopus Google Scholar, Y. Jacobson H.R. Capdevila J.H. Falck J.R. Breyer M.D. Am. J. Physiol. 1995; Google R.C. Homma T. Jacobson H.R. Capdevila J. J. Cell. Physiol. 1990; 144: 429-437Crossref PubMed Scopus (92) Google Scholar, 23Burns K.D. Capdevila J. Wei S. Breyer M.D. Homma T. Harris R.C. Am. J. Physiol. 1995; 269: C831-C840Crossref PubMed Google on D.L. Capdevila J. Falck J.R. Breyer M.D. Jacobson H.R. J. Clin. Invest. 1989; PubMed Scopus Google on vascular A.P. Fleming J.T. Falck J.R. Jacobs E.R. Gebremedhin D. Harder D.R. Roman R.J. Am. J. Physiol. 1996; 270: F822-F832PubMed Google Scholar, T. K. Capdevila J. Karara A. Falck J.R. Jacobson H.R. Am. J. Physiol. 1991; Google of prostaglandin Y. Jacobson H.R. Capdevila J.H. Falck J.R. Breyer M.D. Am. J. Physiol. 1995; Google W.B. Gebremedhin D. Pratt P.F. Harder D.R. Circ. Res. 1996; 78: 415-423Crossref PubMed Scopus (1115) Google Scholar, 42Fisslthaler B. Popp R. Kiss L. Potente M. Harder D.R. Fleming I. Busse R. Nature. 1999; 401: 493-497Crossref PubMed Scopus (809) Google Scholar, J. J.C. Trends Pharmacol. Sci. 2000; 21: Full Text Full Text PDF PubMed Scopus Google K. Huo Y. Ruan X. Yang B. Spiecker M. Ley K. Zeldin D.C. Liao J.K. Science. 1999; 285: 1276-1279Crossref PubMed Scopus (1024) Google K. Ruan X.L. Dai J. Yang S.X. Graham L. Zeldin D.C. Liao J.K. J. Biol. Chem. 2001; 276: 15983-15989Abstract Full Text Full Text PDF PubMed Scopus (212) Google on T. M. E.F. J. Physiol. 1999; PubMed Scopus Google on J. Capdevila J.H. Zeldin D.C. Mol. Pharmacol. 1999; PubMed Scopus Google Scholar, J.R. T. P. M. Am. J. Physiol. 264: Google Scholar, L. J. Physiol. 1998; PubMed Scopus Google on J.R. T. P. M. Am. J. Physiol. 264: Google effects S. Chen W. Murphy E. Gabel S. Tomer K.B. Foley J. Steenbergen C. Falck J.R. Moomaw C.R. Zeldin D.C. J. Biol. Chem. 1997; 272: 12551-12559Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar, B. Graham L. S. Falck J.R. Liao J.K. Zeldin D.C. Mol. Pharmacol. 2001; 60: PubMed Scopus Google in a EETs are endogenous of human and kidney, and EET biosynthesis the A. Dishman E. Jacobson Falck J.R. Capdevila J.H. 1990; PubMed Scopus Google Scholar, T. K. Capdevila J. Karara A. Falck J.R. Jacobson H.R. Am. J. Physiol. 1991; Google Scholar, J. W. Tomer K.B. Moomaw C.R. R. Breyer M.D. Zeldin D.C. J. Biol. Chem. 1999; 274: Full Text Full Text PDF PubMed Scopus Google Scholar, K. Schwartzman M.L. Am. J. Physiol. 1992; 262: Google Scholar). Moreover, EETs have been shown to contribute to either by transport vascular and cellular proliferation or by the of and (3Capdevila J.H. Falck J.R. Harris R.C. J. Lipid Res. 2000; 41: 163-181Abstract Full Text Full Text PDF PubMed Google Scholar, 5Makita K. Falck J.R. Capdevila J.H. FASEB J. 1996; 10: 1456-1463Crossref PubMed Scopus (120) Google Scholar, 6McGiff J.C. Quilley J. Curr. Opin. Nephrol. Hypertens. 2001; 10: 231-237Crossref PubMed Scopus (86) Google R.J. K.G. Harder D.R. M. Clin. Exp. Pharmacol. Physiol. 2000; PubMed Scopus Google Scholar). For example, in the EETs inhibit and the in cytosolic M.F. Madhun Z.T. Hopfer U. Douglas J.G. Adv. Prostaglandin Thromboxane Leukotriene Res. 1991; 21A: 205-208PubMed Google Scholar, Z.T. D. Hopfer U. Douglas J.G. J. Clin. Invest. 1991; PubMed Scopus Google Scholar). In the P450 epoxygenase inhibit the of and and increase cytosolic D.L. Capdevila J. Falck J.R. Breyer M.D. Jacobson H.R. J. Clin. Invest. 1989; PubMed Scopus Google Scholar, Y. Jacobson H.R. Capdevila J.H. Falck J.R. Breyer M.D. Am. J. Physiol. 1995; Google Scholar, T. J. Clin. Invest. PubMed Scopus Google Scholar). The EETs also have potent effects on vascular tone and are in A.P. Fleming J.T. Falck J.R. Jacobs E.R. Gebremedhin D. Harder D.R. Roman R.J. Am. J. Physiol. 1996; 270: F822-F832PubMed Google Scholar, R.C. Homma T. Jacobson H.R. Capdevila J. J. Cell. Physiol. 1990; 144: 429-437Crossref PubMed Scopus (92) Google Scholar, T. K. Capdevila J. Karara A. Falck J.R. Jacobson H.R. Am. J. Physiol. 1991; Google Scholar). In to the effects of EETs on vascular tone and several of that the P450 epoxygenase pathway may be involved in the of the rat are by and their to the of V.R. Makita K. Zaphiropoulos P.G. Capdevila J.H. J. Clin. Invest. 1999; 104: 751-760Crossref PubMed Scopus (110) Google Scholar, J.H. Wei S. J. Karara A. Jacobson H.R. Falck J.R. Guengerich F.P. DuBois R.N. J. Biol. Chem. 1992; Full Text PDF PubMed Google Scholar, T. D. Quilley J. J.C. J. Clin. Invest. 1999; 104: PubMed Scopus Google Scholar, K. K. Karara A. Jacobson H.R. Falck J.R. Capdevila J.H. J. Clin. Invest. 1994; PubMed Scopus Google Scholar). rats have altered epoxygenase and epoxide hydrolase and treatment of with that either P450 or inhibit D. J.C. Schwartzman M.L. Biochem. Pharmacol. PubMed Scopus Google Scholar, C. Parker C. Graham L. Hammock B.D. Zeldin D.C. D.L. Circ. Res. 2000; PubMed Scopus Google Scholar, P. Graham L. J. Zeldin D.C. D.L. Mol. Pharmacol. 2000; Google Scholar, D. J.D. Harder D.R. Roman R.J. J. Vasc. Res. PubMed Scopus Google Scholar). the in the rat of is with an to increase epoxygenase activity in to K. K. Karara A. Jacobson H.R. Falck J.R. Capdevila J.H. J. Clin. Invest. 1994; PubMed Scopus Google Scholar). of the in in the absence and of M. M. K. J.R. J. Biol. Chem. 2000; 275: Full Text Full Text PDF PubMed Scopus Google Scholar). the of epoxygenase is increased in with J. D.J. E. Adv. Prostaglandin Thromboxane Leukotriene Res. 1991; 21A: Google Scholar). a for P450 and in and pathway as an for EETs have been proposed to be endothelial derived hyperpolarizing factors in that they vascular smooth muscle by in the smooth muscle cell membrane (10Campbell W.B. Gebremedhin D. Pratt P.F. Harder D.R. Circ. Res. 1996; 78: 415-423Crossref PubMed Scopus (1115) Google Scholar, 42Fisslthaler B. Popp R. Kiss L. Potente M. Harder D.R. Fleming I. Busse R. Nature. 1999; 401: 493-497Crossref PubMed Scopus (809) Google Scholar, J. J.C. Trends Pharmacol. Sci. 2000; 21: Full Text Full Text PDF PubMed Scopus Google Scholar). that the by which EETs the of the protein with a on the Chen C.L. R. Campbell W.B. Circ. Res. 1999; PubMed Scopus Google Scholar). Treatment of with β-naphthoflavone induces a CYP2C EET biosynthesis, and increases in B. Popp R. Kiss L. Potente M. Harder D.R. Fleming I. Busse R. Nature. 1999; 401: 493-497Crossref PubMed Scopus (809) Google Scholar). Moreover, with an to CYP2C results in CYP2C expression and of vascular that the synthase in the vascular is a CYP2C isoform B. Popp R. Kiss L. Potente M. Harder D.R. Fleming I. Busse R. Nature. 1999; 401: 493-497Crossref PubMed Scopus (809) Google Scholar). EETs have been shown to play important roles the of EETs or of human endothelial cell and EETs to the vascular (21Node K. Huo Y. Ruan X. Yang B. Spiecker M. Ley K. Zeldin D.C. Liao J.K. Science. 1999; 285: 1276-1279Crossref PubMed Scopus (1024) Google Scholar). The for the of the EETs shown to of the factor and (21Node K. Huo Y. Ruan X. Yang B. Spiecker M. Ley K. Zeldin D.C. Liao J.K. Science. 1999; 285: 1276-1279Crossref PubMed Scopus (1024) Google Scholar). In vascular endothelial cells, of EETs or of increased tissue plasminogen activator expression and activity (22Node K. Ruan X.L. Dai J. Yang S.X. Graham L. Zeldin D.C. Liao J.K. J. Biol. Chem. 2001; 276: 15983-15989Abstract Full Text Full Text PDF PubMed Scopus (212) Google Scholar). of by EETs with increased increased intracellular and (22Node K. Ruan X.L. Dai J. Yang S.X. Graham L. Zeldin D.C. Liao J.K. J. Biol. Chem. 2001; 276: 15983-15989Abstract Full Text Full Text PDF PubMed Scopus (212) Google Scholar). the effects the of the EETs by inhibitors that EET effects of their (21Node K. Huo Y. Ruan X. Yang B. Spiecker M. Ley K. Zeldin D.C. Liao J.K. Science. 1999; 285: 1276-1279Crossref PubMed Scopus (1024) Google Scholar, K. Ruan X.L. Dai J. Yang S.X. Graham L. Zeldin D.C. Liao J.K. J. Biol. Chem. 2001; 276: 15983-15989Abstract Full Text Full Text PDF PubMed Scopus (212) Google Scholar). that EETs in the in to their EETs have been shown to have effects on For example, 8,9-EET and produces a in the membrane T. M. E.F. J. Physiol. 1999; PubMed Scopus Google Scholar). J.R. T. P. M. Am. J. Physiol. 264: Google demonstrated that both and 11,12-EET significantly increase cell and intracellular L. J. Physiol. 1998; PubMed Scopus Google that 11,12-EET and intracellular in and that the P450 epoxygenase cell In contrast, have shown that 11,12-EET inhibitory effects on that EETs can either increase or activity on the metabolic and of the J. Capdevila J.H. Zeldin D.C. Mol. Pharmacol. 1999; PubMed Scopus Google Scholar). In an rat 11,12-EET significantly of S. Chen W. Murphy E. Gabel S. Tomer K.B. Foley J. Steenbergen C. Falck J.R. Moomaw C.R. Zeldin D.C. J. Biol. Chem. 1997; 272: 12551-12559Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar). the the of have to an of the and relevance of the AA epoxygenase a of important P450 isoforms are responsible for EET biosynthesis in are the signaling pathways and that the biological of the is the functional relevance of epoxygenase and are they with increased to human The of biological such as and/or the of P450 epoxygenase inhibitors and inhibitory and the of EET will that to and critical to R. B. and Capdevila for their the of for of
Language: English
Subfield: Biochemistry
Open Access status: hybrid
Estimated APC paid: $3,430
OpenAlex ID: W2093486401
FWCI: 1.726
Cites: 81
Cited by: 666
Related to: 10